[HTML][HTML] End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB
D Huang, D Wu, P Wang, Y Wang, W Yuan, D Hu… - Journal of …, 2022 - Elsevier
Background & Aims Functional cure can be sustained in a proportion of patients with chronic
hepatitis B (CHB) who lose hepatitis B surface antigen (HBsAg) after pegylated interferon
alpha (Peg-IFN-ɑ)-based treatment. In this study, we aimed to identify biomarkers
associated with a durable functional cure and to dissect potential immunological
mechanisms. Methods Of 257 nucleos (t) ide analogue-suppressed patients with CHB in the
ANCHOR study, 80 patients randomly assigned to 96-week Peg-IFN-α-based therapy with …
hepatitis B (CHB) who lose hepatitis B surface antigen (HBsAg) after pegylated interferon
alpha (Peg-IFN-ɑ)-based treatment. In this study, we aimed to identify biomarkers
associated with a durable functional cure and to dissect potential immunological
mechanisms. Methods Of 257 nucleos (t) ide analogue-suppressed patients with CHB in the
ANCHOR study, 80 patients randomly assigned to 96-week Peg-IFN-α-based therapy with …